Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 38,782 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 38,782 shares of the stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $0.54, for a total transaction of $20,942.28. Following the completion of the transaction, the director directly owned 2,159,860 shares of the company’s stock, valued at $1,166,324.40. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Luke Evnin also recently made the following trade(s):

• On Thursday, January 15th, Luke Evnin sold 37,413 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.55, for a total transaction of $20,577.15.
• On Wednesday, January 14th, Luke Evnin sold 30,616 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.57, for a total value of $17,451.12.
• On Tuesday, January 13th, Luke Evnin sold 43,198 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.55, for a total value of $23,758.90.
• On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total value of $33,618.60.
• On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total transaction of $15,053.58.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total transaction of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $11,697.84.

Werewolf Therapeutics Trading Up 2.7%

HOWL traded up $0.02 during midday trading on Tuesday, hitting $0.56. 672,657 shares of the company were exchanged, compared to its average volume of 514,380. The firm’s 50 day moving average price is $0.82 and its 200-day moving average price is $1.23. Werewolf Therapeutics, Inc. has a 1-year low of $0.53 and a 1-year high of $2.38. The firm has a market capitalization of $27.40 million, a P/E ratio of -0.35 and a beta of 0.77. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. As a group, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on HOWL shares. HC Wainwright dropped their target price on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Bank of America dropped their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Citigroup downgraded Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. Finally, Citizens Jmp cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Werewolf Therapeutics has a consensus rating of “Hold” and an average target price of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HOWL. Y Intercept Hong Kong Ltd purchased a new position in shares of Werewolf Therapeutics in the second quarter worth about $92,000. Vanguard Group Inc. boosted its holdings in Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after buying an additional 109,796 shares during the period. Bank of America Corp DE grew its stake in Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics in the second quarter worth $409,000. Finally, Citadel Advisors LLC purchased a new position in shares of Werewolf Therapeutics in the third quarter valued at $304,000. 64.84% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.